Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.
In the headlines
Jeito Capital leads €75 million Series B Financing in NMD Pharma, a Danish company, to develop breakthrough treatments for patients with severe neuromuscular diseases
Jeito Capital’s second round of funding will support NMD Pharma in becoming a leading, global, clinical-stage company, with a strong pipeline of breakthrough therapies for patients suffering from severe neuromuscular disorders. This funding round will also contribute...
Find all our press releases
The Series C extension round will accelerate clinical development, manufacturing scale-up and...
Jeito Capital demonstrates European biopharma leadership with first exit with AstraZeneca acquisition of Neogene Therapeutics
Deal validates Jeito’s unique investment model of selecting high-quality assets developed by...
Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer
Jeito Capital co-leads oversubscribed EUR 50 million Series C financing with Brandon Capital...
Jeito Capital becomes significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases
Jeito Capital participates in $120 million financing alongside ARCH Venture Partners and Monograph...
Jeito Capital appoints new team members to support its growth as a European Private Equity fund leader in life sciences
Bastien Renaud is appointed Chief Financial Officer Evaldo Bifulco, Head of Compliance & Risk,...
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis
Aarhus, Denmark, 11 October 2022 - NMD Pharma A/S, a clinical stage biotech company developing...
Face to face
All day long
IPEM Paris 2023
Jeito will be present at IPEM, the International Private Equity Market, an international forum bringing together the major players in private equity.